Amaris Elliott Engel

September 03, 2014 | National Law Journal

Several drugmakers facing a lawsuit from Chicago over allegedly misrepresenting the safety of using their opioid painkillers in the treatment of chronic, non-cancer pain argue that the case should be dismissed because the U.S. Food and Drug Administration has primary jurisdiction over the drugs.

By Amaris Elliott-Engel

3 minute read

September 03, 2014 | National Law Journal

A translator who provided internal Toyota documents to news outlets is facing sanctions for not obeying a protective order in the litigation over the carmaker's vehicles that unexpectedly accelerated.

By Amaris Elliott-Engel

3 minute read

September 03, 2014 | National Law Journal

In an apparent issue of first impression, the survivors of a woman who allege she was exposed to asbestos dust because of laundering her husband's workplace clothes have survived a motion for summary judgment in Alabama federal court.

By Amaris Elliott-Engel

3 minute read

September 03, 2014 | National Law Journal

The federal government has filed a rebuttal to the Pharmaceutical Research & Manufacturers of America's argument that drug companies face liability for engaging in truthful speech about “off-label” uses of drugs.

By Amaris Elliott-Engel

2 minute read

August 29, 2014 | National Law Journal

In an apparent case of first impression, the Alaska Supreme Court has ruled that out-of-state hourly billing rates may not be used to calculate attorney-fee awards except in exceptional circumstances.

By Amaris Elliott-Engel

3 minute read

August 29, 2014 | National Law Journal

Coltec Industries Inc., the parent company and primary equityholder in a gasket maker in bankruptcy, has moved to have an independent examiner look at the $105.2 million in fees paid to attorneys and other professional firms in the proceedings.

By Amaris Elliott-Engel

2 minute read

August 29, 2014 | National Law Journal

C.R. Bard Inc., which is facing close to 8,700 lawsuits over its transvaginal mesh in federal court, is objecting to a discovery request regarding the development of mesh products overseas.

By Amaris Elliott-Engel

2 minute read

August 29, 2014 | National Law Journal

A group of pharmaceutical companies defending their Incretin-based therapies in federal court oppose a motion to compel discovery about adverse events involving their products and reported to the Food and Drug Administration.

By Amaris Elliott-Engel

2 minute read

August 29, 2014 | National Law Journal

The bankruptcy trustee in litigation over a pharmacy that caused a multistate breakout of meningitis from the steroids it compounded has asked to limit the discovery into the pharmacy's owners and insurers after they reached a $100 million settlement.

By Amaris Elliott-Engel

3 minute read

August 28, 2014 | Connecticut Law Tribune

A Connecticut television photographer's federal lawsuit could shed some legal light on how far journalists can go to record police activity and what rights they might have to use drones to gather news.

By Amaris Elliott-Engel

5 minute read